Hemostasiological portrait of multiple myeloma


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

PATIENTS WITH MULTIPLE MYELOMA BECOME NOT RARE PATIENTS OF THE NTPHROLOGICAL CLINIC. CLOSE ATTENTION TO THE HEMOSTATIC SYSTEM IS CONSIDERED AS AN IMPORTANT ASPECT OF THEIR MANAGEMENT. MEANWHILE, THROMBOTIC AND HEMORRHAGIC PROBLEMS IN THIS CATEGORY OF PATIENTS ARE QUITE COMMON, AND CHARACTERIZED BY CLINICAL AND PATHOPHYSIOLOGICAL DIVERSITY. ACCORDINGLY, THEY REQUIRE AN INDIVIDUAL APPROACH, BASED ON A CAREFUL LABORATORY MONITORING.

Full Text

Restricted Access

About the authors

A. Yu Bulanov

SBHCI "City Clinical Hospital № 52" of Moscow Healthcare Department; FSAEI HE "Peoples' Friendship University of Russia"

Email: buldoc68@mail.ru
Doctor of Medical Sciences, Prof at the Department of Anaesthesiology and Emergency Medicine; Head of mobile consultative transfusiological team

I. B Simarova

SBHCI "City Clinical Hospital № 52" of Moscow Healthcare Department

Anesthesiologist-Resuscitator of mobile consultative transfusiological team

References

  1. Miehels Th.С., Petersen К.Е. Multiple myeloma diagnosis and treatment. Am. Fam. Phycian. 2017; 99(6): 373-383.
  2. Tiong I.S., Rodgers S.E., Lee C.H., McRae S.J. Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma. Leuk. Lymphoma. 2017; 58(4): 941-949. doi: 10.1080/10428194.2016.1219900.
  3. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br. J. Haematol. 2009; 145(2): 151-163. doi: 10.1111/j.l365-2141.2008.07577.x.
  4. Van Mariot A.M., Auwerda J.J., Lisman T. Prospective evaluation of coagulopaty in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk. Res. 2008; 32(7): 1078-1084. doi: 10.1016/j.leukres.2007.12.002.
  5. Gogia A., Sikka M., Shrma S., Rusia U. Hemostatic abnormalities in multiple myeloma patients. Asian Рас. J. Cancer Prev. 2017; 19(1): 127-130. doi: 10.22034/APJCP2018.19.1.127.
  6. Аникина E.B., Ксензова Т.Н., Болдырева О.Н. Особенности течения гиперкоагуляционного синдрома у больных множественной миеломой. Тематология и трансфузиология. 2012; (3): 93-94.
  7. Hobbs J. G., Van Slambrouck C., Miller J.L., Yamini B. Intracranial hemorrhage as initial manifestation of plasma cell myeloma: a case report. J. Clin. Neurosci. 2018; 50: 133-135. doi: 10.1016/jjocn.2018.01.054.
  8. Khan Z., Darr U., Renno A. Tiwari A., Sofî A., Nawras A. Massive Upper and Lower GL bleed from simultaneous primary myloidosis of stomach and transverse colon in a patient with multiple myeloma. Case Rep. Gastroenterol. 2017; 11(3): 625-631. doi: 10.1159/000480073.
  9. Borgman C.J. Turk. J. Gastroenterology. 2018; 29: 104-107.
  10. Borgman CJ. Concomitant multiple myeloma spectrum diagnosis in a central retinal vein occlusion: a case report and review. Clin. Exp. Optom. 2016; 99(4): 309-312. doi: 10.1111/cxo.12319.
  11. Gracheva M.A., Umova E.S., Sinauridze E.L., Tarandovskiy L.D., Orel E.B., Poletaev A.V., Mendeleeva L.P., Ataullakhanov F.L., Balandina A.N. Thromboelastography, Trombin generation test and thrombodynamics reveal hypercoagulability in patient with multiple myeloma. Leuk. Lymphoma. 2015; 56(12): 3418-3425.
  12. Fotiou D., Gerotziafas G., Kastritis E., Dimopoulos M.A., Terpos E. A review о the venous thrombotic issues associated with multiple myeloma. Expert Rev. Hematol. 2016; 9(7): 695- 706.
  13. Tzoran L., Brenner B., Hoffman R. Myeloma and thrombotic complications. Minerva Med. 2013; 104(2): 155-160.
  14. Leebeek FW Update of thrombosis in multiple myeloma. Thromb. Res. 2016; 140: 76-80.
  15. Буланов А.Ю. Контроль и коррекция системы гемостаза в перационном периоде у пациентов гематологической клиники. Авт.реф. д.м.н. М., 2013 г.
  16. Sigurdur Y.K. Thrombosis in multiple myeloma. Hematology. 2010; 437-444.
  17. Qiao J., Wu Yu., Wu X., Liu Y., Li X., Ju W., Qi K., Li D., Gardiner E.E., Andrews R.K., Zeng L., Xu K. An absence of platelet activation following thalidomide treatment in vivo or in vitro. Oncotarget. 2017; 8(22): 5776-5782.
  18. Elice F., Fink L., Tricot G., Barlogie B., Zangari M. Acquired resistance to activated protein С. in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br.J. Haematol. 2006; 134(4): 399-405.
  19. Mian H., Warkentin Т.Е., Sheppard J.-A. L., MacDonald A., Linkins L.A., Benger A., Foley R. Autoimmune HLT due to apheresis for heparin flushes for stem cell harvesting before autotransplantation for myeloma. Blood. 2017; 130: 171-1682. doi: 10.1182/blood-2017-06-788679.
  20. Lshiguro K., Hayashi T., Yokoyama Y., Aoki Y., Onodera K., Lkeda H., Lshida T., Nakase H. Elevation of plasmin-a2-plasmin inhibitor complex predicts the diagnosis of systemic AL amiloidosis in patients with monoclonal protein. Lnternal Med. 2018; 57: 778-783. doi: 10.2169/internalmedicine.8999-17.
  21. Sigurdur Y.K. Thrombosis in multiple myeloma. Hematology. 2010; 437-444.
  22. Буланов А.Ю., Яцков К.В., Шулутко E.М., Глухова Т.Е., Андрейченко С.А. Эндогенный гепариноподобный синдром: анализ клинических наблюдений. Анестезиология и реаниматология. 2012; 3: 51-54.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies